Somatropin (recombinant deoxyribonucleic acid [rDNA] origin)
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Growth Hormone (GH) Deficiency
Conditions
Growth Hormone (GH) Deficiency, Short Stature Homeobox Containing Gene (SHOX) Deficiency, SHOX Deficiency-related Disorder, Non-GH-deficient Growth Disorders
Trial Timeline
Apr 1, 1999 → Sep 1, 2015
NCT ID
NCT01088412About Somatropin (recombinant deoxyribonucleic acid [rDNA] origin)
Somatropin (recombinant deoxyribonucleic acid [rDNA] origin) is a pre-clinical stage product being developed by Eli Lilly for Growth Hormone (GH) Deficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT01088412. Target conditions include Growth Hormone (GH) Deficiency, Short Stature Homeobox Containing Gene (SHOX) Deficiency, SHOX Deficiency-related Disorder.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01088412 | Pre-clinical | Completed |
Competing Products
20 competing products in Growth Hormone (GH) Deficiency
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Somatropin | Eli Lilly | Phase 3 | 77 |
| HER3-DXd | Daiichi Sankyo | Pre-clinical | 23 |
| Erlotinib | Astellas Pharma | Phase 2 | 52 |
| radio-labeled naquotinib + naquotinib | Astellas Pharma | Phase 1 | 33 |
| pegylated Somatropin + pegylated Somatropin + Jintropin AQ | Sun Pharmaceutical | Phase 2 | 52 |
| PEG-somatropin | Sun Pharmaceutical | Approved | 85 |
| PEG-somatropin + PEG-somatropin | Sun Pharmaceutical | Approved | 85 |
| PEG-somatropin | Sun Pharmaceutical | Phase 3 | 77 |
| Somatropin + Somatropin | Eli Lilly | Phase 3 | 77 |
| Somatropin + Somatropin | Eli Lilly | Phase 3 | 77 |
| somatropin, rDNA origin, for injection | Eli Lilly | Phase 3 | 77 |
| Sterile becaplermin gel vs. sterile placebo gel treatment 1 | Johnson & Johnson | Pre-clinical | 23 |
| ABT-414 | AbbVie | Pre-clinical | 23 |
| Saizen® A + Saizen® B | Merck | Phase 3 | 77 |
| Saizen® solution for injection (referred as Saizen®) | Merck | Approved | 85 |
| Cetuximab + FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan) | Merck | Phase 3 | 77 |
| Saizen + Saizen | Merck | Approved | 85 |
| Miransertib | Merck | Phase 2 | 52 |
| Miransertib | Merck | Phase 1/2 | 41 |
| ARX201 + ARX201 + ARX201 | Merck | Phase 2 | 52 |